Veracor Capital vs. Traditional PE
Not all healthcare private equity is created equal. Compare our outcomes-focused approach to traditional models that optimize for recurring revenue.
What Sets Us Apart
Outcomes Over Revenue
We invest in companies where healed patients are better than lifetime customers. Traditional PE optimizes for recurring revenue — we optimize for resolution.
Proprietary Methodology
Signal-Based Medicine isn't a marketing term — it's a 20+ year developed approach with documented results. No traditional fund has this proprietary access.
Aligned Incentives
Our founder invests personal capital alongside LPs. We don't participate in carry until investors receive their preferred return. Alignment isn't optional.
Vertical Integration
Our portfolio companies create value for each other. Patient referrals, shared infrastructure, unified provider networks — synergies that isolated investments can't replicate.
Side-by-Side Comparison
| Category | Traditional Healthcare PE | Veracor Capital |
|---|---|---|
| Investment Philosophy | Optimize for recurring revenue and patient dependency | Invest in companies that actually heal patients |
| Healthcare Outcomes | 60-70% industry average success rates | 95% documented success rate across portfolio |
| Investment Thesis | Diversified across unrelated healthcare assets | Signal-Based Medicine with proprietary methodology |
| Portfolio Structure | Disparate companies competing for same patients | Vertically integrated ecosystem with synergies |
| Founder Alignment | Management fees prioritized over carry | Founder capital invested alongside LPs |
| Fee Structure | 2% management + 20% carry (standard) | 2% management + 20% carry with 8% hurdle |
| Impact Measurement | ESG metrics often secondary or cosmetic | Impact built into model — outcomes drive returns |
| Operational Expertise | Financial engineering focus | 20+ years healthcare operations experience |
| Deal Flow | Competitive auction processes | Proprietary access to Kure Health ecosystem |
| Track Record | Established multi-decade histories | 47,000+ patients healed, emerging fund platform |
Outcomes vs. Revenue
Traditional healthcare PE optimizes for recurring revenue. This incentivizes disease management, not healing. Patients become lifetime customers — and that's the business model.
Veracor Capital flips this model. We invest in companies where healed patients create more value than dependent ones. Signal-Based Medicine produces actual resolution, not perpetual treatment.
As healthcare shifts to value-based reimbursement, outcomes-focused companies will outperform disease-management models. We're positioning ahead of this inevitable transition.
Traditional Model
Industry Standard"Patient lifetime value is maximized when conditions are managed, not cured."
Veracor Model
Our Approach"Healed patients become advocates. Outcomes drive referrals, reputation, and returns."
Frequently Asked Questions
Why choose Veracor Capital over a traditional healthcare PE fund?
Veracor Capital offers proprietary access to Signal-Based Medicine — a documented methodology with 95% success rates that no traditional fund possesses. We invest in an integrated ecosystem where companies strengthen each other, rather than competing for the same patients. Our founder invests alongside LPs, ensuring aligned incentives.
What is Signal-Based Medicine and why does it matter for investors?
Signal-Based Medicine is a healthcare approach that identifies and corrects biological dysfunction at the cellular level, rather than treating symptoms. For investors, this means portfolio companies that produce documented healing (not lifetime disease management), creating sustainable value through outcomes-based reimbursement models.
How does Veracor Capital's track record compare to established PE firms?
While Veracor Capital is an emerging fund platform, the underlying methodology and portfolio companies have 20+ years of development and 47,000+ documented patient cases. Traditional PE may offer longer fund track records, but few can demonstrate the clinical outcomes and proprietary methodology that differentiates our approach.